Reducing 14 ‘modifiable’ risks can prevent or delay cognitive disorder, report says
Eisai and Biogen face uphill battle to win EU approval for Leqembi after committee’s ruling
GSK’s Shingrix is latest drug to show potential for targeting previously untreatable brain disorders
Decision to associate charity with a cure turned it into Europe’s biggest funder of dementia research
New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Independent experts conclude unanimously that the experimental treatment is effective
Japanese pharma group takes on new jab that makes immune system attack dangerous protein build-up in brain
High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
Worldwide study finds neurological conditions affect billions as life expectancy rises
Breakthrough medicine will now be subject to further review by committee of independent experts
With ageing populations and dementia rates rising fast, the family home — worth more than ever before — is increasingly the focus of discord
Research by Which? reveals huge disparity between the best and the worst
Large study further boosts fast-evolving efforts to predict and prevent neurogenerative diseases
Cases connected to growth hormone extracted from cadavers show disease’s parallels with CJD brain disorder
Swedish trial finds ‘high accuracy’ in identifying protein associated with toxic build-up in the brain
Boom in asset prices and increased prevalence of dementia drive costly family squabbles over wills
Further research on its underlying causes and preventive action is essential
Emerging research is challenging a widely held belief that new cases of the condition will rise exponentially as people live longer
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
AstronauTx’s financing is step towards helping millions of people suffering from disease
Promising trial results will not end scientific debate over the disease, but they further validate pharmaceutical research
Dementia experts hail ‘watershed moment’ after trial results for donanemab antibody treatment
Move by Food and Drug Administration paves way for millions of Americans to access medicine
A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise
